GlassScriptPhysician profile
James A Saidi
NPI 1194792820
$2,660.25
in general payments reported to CMS, 2019-2025
31 companies · $768 in 2025
The $768 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $173 · 2021: $242 · 2022: $36.60 · 2023: $309 · 2024: $198 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $364.96 | 2019-2024 | Xtandi |
| Teleflex LLC | $284.53 | 2021-2023 | Urolift |
| Axonics, INC. | $193.12 | 2020-2024 | Axonics |
| Janssen Biotech, INC. | $192.26 | 2019-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $181.98 | 2019-2025 | |
| Pfizer INC. | $163.08 | 2019-2025 | |
| Progenics Pharmaceuticals, INC. | $146.23 | 2025 | |
| Janssen Scientific Affairs, LLC | $144.66 | 2025 | Erleada |
| Blue Earth Diagnostics | $112.43 | 2019 | |
| Sumitomo Pharma America, INC. | $90.94 | 2024-2025 | Gemtesa |
| Procept Biorobotics Corporation | $89.74 | 2020 | |
| Tolmar, INC. | $87.15 | 2024-2025 | Eligard, Jatenzo |
| Neotract INC. | $70.79 | 2019-2020 | |
| Boston Scientific Corporation | $67.74 | 2021-2025 | Axonics |
| Valencia Technologies Corporation | $59.58 | 2025 | Ecoin Device Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $58.88 | 2019-2025 | Provenge |
| Tolmar Pharmaceuticals, INC. | $54.76 | 2019-2021 | |
| Urogen Pharma, INC. | $46.33 | 2021-2025 | |
| Olympus America INC. | $45.86 | 2021-2025 | Itind System |
| Accord Healthcare, INC. | $21.23 | 2024 | |
| Immunitybio, INC. | $21.07 | 2025 | |
| Axogen | $20.73 | 2025 | |
| Myovant Sciences INC. | $19.03 | 2021 | |
| Srs Medical Systems, INC. | $17.92 | 2021 | |
| Medtronic USA, INC. | $16.95 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.79 | 2025 | Azmiro |
| Ferring Pharmaceuticals INC. | $15.24 | 2025 | Adstiladrin |
| Abbvie INC. | $15.00 | 2019 | |
| Urovant Sciences INC | $14.58 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $13.98 | 2024 | Bard Urinary Drainage Bag |
| Coloplast Corp | $13.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Saidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.